BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lau G, Yu ML, Wong G, Thompson A, Ghazinian H, Hou JL, Piratvisuth T, Jia JD, Mizokami M, Cheng G, Chen GF, Liu ZW, Baatarkhuu O, Cheng AL, Ng WL, Lau P, Mok T, Chang JM, Hamid S, Dokmeci AK, Gani RA, Payawal DA, Chow P, Park JW, Strasser SI, Mohamed R, Win KM, Tawesak T, Sarin SK, Omata M. APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy. Hepatol Int 2021;15:1031-48. [PMID: 34427860 DOI: 10.1007/s12072-021-10239-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Abdelbary MS, Samir R, El-nahaas SM, Hosny Shahin RM, El-sayed M, Gaber Y, Tantawi O, Zayed NA, Yosry A. Hepatitis B reactivation following eradication of HCV with direct-acting antiviral drugs (DAAs) in a cohort of patients from different institutions in Egypt. Journal of Clinical and Experimental Hepatology 2022. [DOI: 10.1016/j.jceh.2022.04.020] [Reference Citation Analysis]
2 Sagnelli C, Sica A, Creta M, Borsetti A, Ciccozzi M, Sagnelli E. Prevention of HBV Reactivation in Hemato-Oncologic Setting during COVID-19. Pathogens 2022;11:567. [DOI: 10.3390/pathogens11050567] [Reference Citation Analysis]
3 Yip TC, Gill M, Wong GL, Liu K. Management of hepatitis B virus reactivation due to treatment of COVID-19. Hepatol Int 2022. [PMID: 35235148 DOI: 10.1007/s12072-022-10306-x] [Reference Citation Analysis]
4 Amano H, Kanda T, Mochizuki H, Kojima Y, Suzuki Y, Hosoda K, Ashizawa H, Miura Y, Tsunoda S, Hirotsu Y, Ohyama H, Kato N, Moriyama M, Obi S, Omata M. The Use of Electronic Medical Records-Based Big-Data Informatics to Describe ALT Elevations Higher than 1000 IU/L in Patients with or without Hepatitis B Virus Infection. Viruses 2021;13:2216. [PMID: 34835022 DOI: 10.3390/v13112216] [Reference Citation Analysis]
5 Liu YC, Hsu CM, Hsiao SY, Hsiao HH. Hepatitis B Virus Infection in Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation. J Pers Med 2021;11:1108. [PMID: 34834460 DOI: 10.3390/jpm11111108] [Reference Citation Analysis]
6 Huang W, Du L, Tang H. Hepatitis B virus reactivation: overview and management. Future Virology 2021;16:821-35. [DOI: 10.2217/fvl-2021-0275] [Reference Citation Analysis]
7 Sausen DG, Bhutta MS, Gallo ES, Dahari H, Borenstein R. Stress-Induced Epstein-Barr Virus Reactivation. Biomolecules 2021;11:1380. [PMID: 34572593 DOI: 10.3390/biom11091380] [Reference Citation Analysis]
8 Cai C, Zhang HF, Yang NB, Lu MQ. Immune checkpoint inhibitors in chronic hepatitis B: therapy or high-risk factor for reactivation? Hepatol Int 2022. [PMID: 35332508 DOI: 10.1007/s12072-022-10317-8] [Reference Citation Analysis]
9 Cheng PN, Liu CJ, Chen CY, Tseng KC, Lo CC, Peng CY, Lin CL, Chiu HC, Chiu YC, Chen PJ. Entecavir Prevents HBV Reactivation During Direct Acting Antivirals for HCV/HBV Dual Infection: A Randomized Trial. Clin Gastroenterol Hepatol 2021:S1542-3565(21)01270-2. [PMID: 34864158 DOI: 10.1016/j.cgh.2021.11.032] [Reference Citation Analysis]
10 Lau G, Yu ML, Wong G, Thompson A. Are immune-checkpoint inhibitors immunosuppressive to hepatitis B virus? Hepatol Int 2022. [PMID: 35229274 DOI: 10.1007/s12072-022-10318-7] [Reference Citation Analysis]